REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
Clinical trial NCT03515629 · TERMINATED
Trial details
- NCT number
- NCT03515629
- Sponsor
- Regeneron Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-02
- Primary completion
- 2021-07-29
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.